Financials · KEQU

Kewaunee Scientific Corporation (KEQU) financials

For the twelve months ended Jul 31, 2026, Kewaunee Scientific Corporation reported $277.21M of revenue and $8.23M of net income.

Revenue, TTM
$277.21M
Revenue growth, YoY
+5.3%
Net income, TTM
$8.23M
Net income growth, YoY
-33.1%
Net margin
3.0%
Free cash flow, TTM
$10.88M
EPS, diluted, TTM
$2.76
EPS growth, YoY
-33.2%
Cash
$8.25M
Total debt
$18.83M
P/E
12.19
P/S
0.36
Market cap
$100.4M
Annual revenue$282.00M
FY2017FY2026
Annual net income$9.62M
FY2017FY2026
Annual free cash flow$14.70M
FY2017FY2026

KEQU revenue and earnings growth

KEQU revenueQ1 2027$66.32M

Quarter YoY
-6.7%
QoQ
-7.1%
FY YoY
+17.3%
5Y CAGR
+13.8%
10Y CAGR
+8.2%

KEQU revenue was $66.32M in fiscal Q1 2027 (ended Jul 31, 2026), down 6.7% from a year earlier and down 7.1% from the prior quarter. For the full fiscal 2026 it was $282.00M, up 17.3% from fiscal 2025. Compound annual growth was +13.8% over 5 years and +8.2% over 10 years. It rose in 7 of the last 10 fiscal years. Fiscal 2026 is the highest of the 15 fiscal years on file.

KEQU net incomeQ1 2027$1.71M

Quarter YoY
-44.8%
QoQ
-49.6%
FY YoY
-15.7%
10Y CAGR
+9.7%

KEQU net income was $1.71M in fiscal Q1 2027 (ended Jul 31, 2026), down 44.8% from a year earlier and down 49.6% from the prior quarter. For the full fiscal 2026 it was $9.62M, down 15.7% from fiscal 2025. Compound annual growth was +9.7% over 10 years. It rose in 1 of the last 3 fiscal years.

KEQU EPSQ1 2027$0.58

Quarter YoY
-44.2%
QoQ
-48.7%
FY YoY
-15.9%
10Y CAGR
+8.5%

KEQU diluted EPS was $0.58 in fiscal Q1 2027 (ended Jul 31, 2026), down 44.2% from a year earlier and down 48.7% from the prior quarter. For the full fiscal 2026 it was $3.22, down 15.9% from fiscal 2025. Compound annual growth was +8.5% over 10 years.

KEQU free cash flowQ1 2027$1.20M

Quarter YoY
-76.0%
QoQ
-73.4%
FY YoY
+16.5%
10Y CAGR
+11.2%

KEQU free cash flow was $1.20M in fiscal Q1 2027 (ended Jul 31, 2026), down 76.0% from a year earlier and down 73.4% from the prior quarter. For the full fiscal 2026 it was $14.70M, up 16.5% from fiscal 2025. Compound annual growth was +11.2% over 10 years.

Export CSV

Income statement

Income statement
Line item
Apr 30, 2026
Apr 30, 2025
Apr 30, 2024
Apr 30, 2023
Apr 30, 2022
Apr 30, 2021
Apr 30, 2020
Apr 30, 2019
Apr 30, 2018
Apr 30, 2017
Revenue$282.00M$240.47M$203.75M$219.49M$168.87M$147.47M$147.54M$146.55M$158.05M$138.56M
Cost of revenue$201.56M$171.62M$151.70M$183.91M$144.65M$123.48M$124.11M$121.23M$125.89M$111.95M
Gross profit$80.44M$68.86M$52.05M$35.59M$24.22M$23.99M$23.43M$25.32M$32.16M$26.61M
Research and development$898.0K$919.0K$920.0K$1.01M$990.0K$1.41M$1.82M$1.55M$1.54M$1.16M
Operating income$16.71M$17.76M$18.28M$5.36M-$2.61M-$1.32M-$2.35M$2.11M$9.92M$6.54M
Interest expense$3.86M$3.21M$1.80M$1.73M$632.0K$389.0K$493.0K$367.0K$299.0K$292.0K
Pre-tax income$13.73M$14.79M$13.12M$4.50M-$2.48M-$2.62M-$2.87M$2.13M$9.62M$6.75M
Income tax$3.27M$3.20M-$5.94M$3.14M$3.52M$990.0K$1.76M$446.0K$4.16M$2.13M
Net income$9.62M$11.40M$18.75M$738.0K-$6.13M-$3.67M-$4.69M$1.53M$5.28M$4.51M
EPS, basic$3.36$3.98$6.51$0.26-$2.20-$1.33-$1.70$0.56$1.94$1.67
EPS, diluted$3.22$3.83$6.38$0.25-$2.20-$1.33-$1.70$0.55$1.90$1.66
Diluted shares3.0M3.0M2.9M2.9M2.8M2.8M2.8M2.8M2.8M2.7M

Balance sheet

Balance sheet
Line item
Apr 30, 2026
Apr 30, 2025
Apr 30, 2024
Apr 30, 2023
Apr 30, 2022
Apr 30, 2021
Apr 30, 2020
Apr 30, 2019
Apr 30, 2018
Apr 30, 2017
Cash and equivalents$9.95M$17.16M$25.94M$13.81M$6.89M$5.73M$5.21M$11.16M$10.96M$13.94M
Receivables$58.74M$62.38M$45.06M$46.08M$41.25M$32.88M$28.06M$33.26M$32.66M$29.89M
Inventory$30.53M$32.85M$20.68M$21.89M$23.80M$16.52M$15.33M$17.21M$18.55M$14.94M
Current assets$105.40M$118.36M$96.82M$87.92M$91.56M$60.46M$54.23M$65.36M$64.39M$59.81M
Goodwill$12.49M$12.49M$0-------
Total assets$178.31M$194.65M$134.77M$118.90M$118.77M$89.38M$83.93M$87.22M$85.08M$80.92M
Current liabilities$48.35M$53.71M$40.78M$40.05M$42.29M$34.18M$27.06M$32.73M$27.62M$26.93M
Short-term debt$5.00M$3.00M$3.10M$3.59M$1.59M$6.83M$4.72M$1.17M$1.17M$918.0K
Long-term debt$15.08M$34.69M-----$229.0K$1.26M-
Total debt$20.08M$37.69M----$0$1.40M$2.43M$2.43M
Total liabilities$101.50M$128.41M$78.56M$80.41M$82.59M$47.90M$45.23M$39.52M$36.89M$37.66M
Shareholders' equity$74.72M$64.46M$54.76M$37.41M$35.69M$41.24M$38.41M$47.10M$47.73M$43.46M

Cash flow

Cash flow
Line item
Apr 30, 2026
Apr 30, 2025
Apr 30, 2024
Apr 30, 2023
Apr 30, 2022
Apr 30, 2021
Apr 30, 2020
Apr 30, 2019
Apr 30, 2018
Apr 30, 2017
Operating cash flow$18.63M$14.78M$19.56M-$3.79M-$7.88M$912.0K$4.16M$2.49M$3.18M$11.66M
Capital expenditures$3.94M$2.17M$4.37M$4.15M$1.91M$2.40M$2.46M$4.21M$3.40M$2.61M
Free cash flow$14.70M$12.62M$15.19M-$7.94M-$9.79M-$1.49M$1.70M-$1.72M-$212.0K$9.05M
Investing cash flow-$3.94M-$30.90M-$4.37M-$4.15M-$1.91M-$2.40M-$2.46M-$4.21M-$3.40M-$2.48M
Financing cash flow-$19.33M$7.41M-$3.01M$14.93M$11.03M$1.98M-$7.46M$2.33M-$2.48M-$2.08M
Dividends paid-----$0$1.04M$2.03M$1.79M$1.57M
Share repurchases$0$1.60M$2.00M$0------
Stock-based compensation$2.13M$1.44M$1.03M$886.0K$729.0K$634.0K$251.0K$197.0K$355.0K$199.0K
Depreciation and amortization$6.28M$4.76M$3.13M-------

Key ratios

Key ratios
Line item
Apr 30, 2026
Apr 30, 2025
Apr 30, 2024
Apr 30, 2023
Apr 30, 2022
Apr 30, 2021
Apr 30, 2020
Apr 30, 2019
Apr 30, 2018
Apr 30, 2017
Revenue growth, YoY17.3%18.0%-7.2%30.0%14.5%-0.0%0.7%-7.3%14.1%7.7%
Net income growth, YoY-15.7%-39.2%2441.1%-----71.0%17.0%18.8%
EPS growth, YoY-15.9%-40.0%2452.0%-----71.1%14.5%16.9%
Gross margin28.5%28.6%25.5%16.2%14.3%16.3%15.9%17.3%20.3%19.2%
Operating margin5.9%7.4%9.0%2.4%-1.5%-0.9%-1.6%1.4%6.3%4.7%
Net margin3.4%4.7%9.2%0.3%-3.6%-2.5%-3.2%1.0%3.3%3.3%
Free cash flow margin5.2%5.2%7.5%-3.6%-5.8%-1.0%1.1%-1.2%-0.1%6.5%
Return on equity12.9%17.7%34.2%2.0%-17.2%-8.9%-12.2%3.2%11.1%10.4%
Return on assets5.4%5.9%13.9%0.6%-5.2%-4.1%-5.6%1.8%6.2%5.6%
Current ratio2.182.202.372.202.171.772.002.002.332.22
Debt to equity0.270.58----0.000.030.050.06

Source: XBRL data Kewaunee Scientific Corporation files with the SEC, latest filing dated Sep 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

KEQU peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
KEQU$277.21M+5.3%$8.23M3.0%$100.4M
UNH$449.66B+3.3%$15.88B3.5%$313.53B
ELV$201.83B+3.6%$5.13B2.5%$86.60B
CI$286.32B+6.8%$5.99B2.1%$75.20B
HUM$154.19B+22.0%$1.25B0.8%$46.33B
NTRA$2.91B+37.4%-$164.71M-5.7%$41.98B
CNC$203.90B+9.7%$1.46B0.7%$33.39B
ILMN$4.54B+5.8%$895.00M19.7%$31.75B
LH$14.59B+6.0%$1.00B6.9%$30.11B

KEQU FAQ

9 questions
  • What is KEQU revenue?
    Kewaunee Scientific Corporation (KEQU) reported $277.21M of revenue for the twelve months ended Jul 31, 2026. That is up 5.3% from the year before. Revenue for fiscal 2026 was $282.00M.
  • Is KEQU profitable?
    Yes. Kewaunee Scientific Corporation earned $8.23M in net income for the twelve months ended Jul 31, 2026, a net margin of 3.0%.
  • How much cash and debt does KEQU have?
    Kewaunee Scientific Corporation reported $8.25M in cash and cash equivalents and $18.83M of debt on its most recent balance sheet in SEC filings.
  • How fast is KEQU revenue growing?
    Kewaunee Scientific Corporation's revenue changed +17.3% in fiscal 2026, to $282.00M. Its compound annual growth rate was +13.8% over 5 years and +8.2% over 10 years.
  • What is KEQU gross margin?
    Kewaunee Scientific Corporation's gross profit was $79.15M on $277.21M of revenue for the twelve months ended Jul 31, 2026, a gross margin of 28.6%.
  • What is KEQU free cash flow?
    Kewaunee Scientific Corporation generated $10.88M of free cash flow for the twelve months ended Jul 31, 2026, which is operating cash flow of $14.82M less capital expenditures.
  • What is KEQU earnings per share?
    Diluted earnings per share were $2.76 for the twelve months ended Jul 31, 2026, from SEC filings, restated for any stock split those filings show.
  • When did KEQU last report financial results?
    The latest statements here come from Kewaunee Scientific Corporation's 10-Q filed on Sep 11, 2026, covering the period ended Jul 31, 2026.
  • Where does this KEQU financial data come from?
    Quantisnow builds these statements from the structured XBRL data Kewaunee Scientific Corporation files with the SEC. It is provided for information only and is not investment advice.